血清解整合素样-金属蛋白酶8、血浆M_2型丙酮酸激酶检测早期诊断非小细胞肺癌价值研究  

Value of ADAM8 and M_2-PK to the diagnosis of non-small cell lung cancer in the early stage

作　　者：周燕斌[1] 曾显声[2] 薛聃[1] 谭潇琼[1] 黄茂宏[1] 

机构地区：[1]中山大学附属第一医院呼吸内科,广州市510080 [2]深圳市福田区慢性病防治院

出　　处：《中华实用诊断与治疗杂志》2010年第2期116-118,共3页Journal of Chinese Practical Diagnosis and Therapy

基　　金：广东省自然科学基金资助项目(编号:06300788)

摘　　要：目的:探讨血清解整合素样-金属蛋白酶8、血浆M2型丙酮酸激酶检测对早期诊断非小细胞肺癌的价值。方法:用ELISA法检测72例非小细胞肺癌患者,30例良性肺疾病患者和30例健康志愿者血清中的解整合素样-金属蛋白酶8浓度和EDTA抗凝血浆中的M2型丙酮酸激酶浓度,行组间比较,以ROC曲线评价诊断价值并相互比较。结果:非小细胞肺癌组血清解整合素样-金属蛋白酶8浓度和血浆M2型丙酮酸激酶浓度均明显高于良性肺疾病组和健康对照组,差异均有统计学意义(P<0.01)。解整合素样-金属蛋白酶8、M2型丙酮酸激酶、癌胚抗原的AUC分别为0.85、0.87、0.90,诊断界值分别取328pg/mL、16.5u/mL、5ng/mL时,其灵敏度分别为76.4%、75.0%、75.0%,特异度分别为83.4%,85.0%,86.7%。结论:解整合素样-金属蛋白酶8和M2型丙酮酸激酶检测对非小细胞肺癌诊断均有较好的价值。Objective To evaluate the diagnostic value of serum ADAM8 and EDTA-plasma M2-PK to non-small cell lung cancer in the early stage. Methods Serum ADAM8 and plasma M2-PK levels were measured with ELISA in 72 patients with non-small cell lung cancer,30 with benign lung disease and 30 normal volunteers. The diagnostic values were evaluated by ROC curve and were compared. Results Serum ADAM8 levels and plasma M2-PK levels were significantly higher in patients with non-small cell lung cancer than in those of benign lung disease group and normal volunteers,which showed statistic differences（P〈0.05）. The AUCs of ADMA8,M2-PK and carcinoembroynit antigen were 0.85,0.87 and 0.90 respectively. Taking 328 pg/mL,16.5 u/mL and 5 ng/mL as cut-off points,the sensitivities were 76.4%,75.0% and 75.0% and the specificities were 83.4%,85.0% and 86.7% respectively. Conclusion Detection of serum ADAM8 and plasma M2-PK is useful for the diagnosis of non-small cell lung cancer.

关 键 词：非小细胞肺癌 整合素样-金属蛋白酶8 M2型丙酮酸激酶 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]